期刊
JOURNAL OF VIROLOGY
卷 84, 期 3, 页码 1214-1220出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01927-09
关键词
-
类别
资金
- Cancer Research UK
- National Institutes of Health [P50 CA098252, RO1 CA118790, RO1 CA133749]
- American Cancer Society [RSG-08-116-01-CCE]
- GSK
Vaccines against the human papillomaviruses (HPVs) most frequently associated with cancer of the cervix are now available. These prophylactic vaccines, based on virus-like particles (VLPs), are extremely effective, providing protection from infection in almost 100% of cases. However, the vaccines present some limitations: they are effective primarily against the HPV type present in the vaccine, are expensive to produce, and need a cold chain. Vaccines based on the minor capsid protein L2 have been very successful in animal models and have been shown to provide a good level of protection against different papillomavirus types. The potential of L2-based vaccines to protect against many types of HPVs is discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据